C-Reactive Protein [9007-41-4]

Athens Research

C-Reactive Protein [9007-41-4]

9

In Vitro Diagnostics, Inflammation, Complement System, Cardiovascular Disease, Rheumatoid Arthritis, Cancer, Alzheimer's

Research Use Only

≥95% by SDS-PAGE

C-reactive protein

C-reactive protein (CRP), an acute-phase reactant, belongs to the pentraxin family characterized by calcium-dependent ligand binding. Each 24 kDa subunit contains a phosphocholine (PC)-binding site on its recognition face, enabling opsonization of pathogens and apoptotic cells via exposed PC moieties on bacterial membranes or oxidized low-density lipoprotein (OxLDL). CRP activates the classical complement pathway by binding C1q and Fcgamma receptors, enhancing phagocytosis and inflammatory cytokine release. Under inflammatory conditions, pentameric CRP (pCRP) dissociates into pro-inflammatory monomers (mCRP) at sites of endothelial activation, amplifying leukocyte adhesion and vascular permeability. Clinically, CRP serves as a biomarker for systemic inflammation, with plasma levels rising from 200 mg/L in severe sepsis or trauma. Elevated baseline high-sensitivity CRP (hs-CRP more then3 mg/L) predicts cardiovascular events, correlating with atherosclerosis progression and endothelial dysfunction. In oncology, CRP more then10 mg/dL portends poor prognosis in pancreatic cancer, reflecting tumor-associated inflammation. CRP also links metabolic dysregulation, with levels more then2.9 mg/L increasing type 2 diabetes risk via IL-6-mediated insulin resistance6. Autoimmune disorders like rheumatoid arthritis show CRP elevation proportional to disease activity, while Alzheimer’s disease involves CRP binding amyloid-bèta plaques to modulate neuroinflammation.

more then 1 year

Plasma shown to be non-reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.

≤ -80° C

41116100